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Classical population genetics shows that varying permutations of genes and risk factors permit or disallow the eﬀects of causative
agents, depending on circumstance. For example, genes and environment determine whether a fox kills black or white rabbits
on snow or black ash covered islands. Risk promoting eﬀects are diﬀerent on each island, but obscured by meta-analysis or
GWAS data from both islands, unless partitioned by diﬀerent contributory factors. In Alzheimer’s disease, the foxes appear to
be herpes, borrelia or chlamydial infection, hypercholesterolemia, hyperhomocysteinaemia, diabetes, cerebral hypoperfusion,
oestrogen depletion, or vitamin A deﬁciency, all of which promote beta-amyloid deposition in animal models—without the aid
of gene variants. All relate to risk factors and subsets of susceptibility genes, which condition their eﬀects. All are less prevalent
in convents, where nuns appear less susceptible to the ravages of ageing. Antagonism of the antimicrobial properties of beta-
amyloid by Abeta autoantibodies in the ageing population, likely generated by antibodies raised to beta-amyloid/pathogen protein
homologues, may play a role in this scenario. These agents are treatable by diet and drugs, vitamin supplementation, pathogen
detection and elimination, and autoantibody removal, although again, the beneﬁcial eﬀects of individual treatments may be
tempered by genes and environment.
1.Introduction
If there is one factor common to complex polygenic diseases
itistheheterogeneityinbothgeneandriskfactorassociation
studies.
Although these have discovered key genes and risk fac-
tors, the results for most are invariably confounded by
conﬂicting data [1]. In the genetic arena, the clear familial
component of many diseases has driven the search for major
genes using genome-wide association studies (GWAS) with
large numbers of patients pooled from diﬀerent regions [2].
Suchstudieshavebeenabletodiscoverrarevariantsthatplay
a major role in a small percentage of patients, for example
VIPR2 in schizophrenia [3]. However, in complex diseases,
these have failed to ﬁnd major genes relevant to all patients
[4], instead unearthing yet more genes of small eﬀect, whose
risk promoting eﬀects are yet again contested, as is the case
with CR1 and PICALM, which have not been conﬁrmed as
risk factors for Alzheimer’s disease in Chinese patients [5]
despite extensive evidence in Caucasian studies [6]. GWAS
studies have, however, been more successful in uncovering
larger numbers of genes of greater eﬀect for simpler traits
such as lipid levels [7].
Viruses and other pathogens have been implicated as risk
factorsinmanydiseases,althoughagain,conﬂictingevidence
leads to scepticism in many areas. For example, the involve-
ment of the Epstein-Barr virus in multiple sclerosis is hotly
contested [8–10].2 ISRN Neurology
Gene-gene and gene-environment interactions may play
an important role in such inconsistency. For example, the
risk promoting eﬀects of genes can be better explained when
using pathway analysis or combining the eﬀects of genes
with common function, rather than by studying single genes
in isolation [11, 12]. Genes and risk factors can also act
together, and in certain cases genes can be linked to environ-
mental variables. For example, many of the genes implicated
in schizophrenia or Alzheimer’s disease are involved in the
life cycles of the pathogens involved in the diseases [13, 14].
Environment-environment interactions are also apparent.
For example, the eﬀects of vitamin E on lifespan, or on
resistance to various infections can be null, deleterious, or
protective, depending on confounding factors such as age,
exercise, smoking, and vitamin C consumption [15–17].
Complex diseases are also composed of many endophe-
notypes or underlying pathologies, and diﬀerent genes or
risk factors may contribute to any of these. Many diﬀerent
processes contribute to cell death in Alzheimer’s disease, for
example, beta amyloid, glutamate, calcium, or free radical
mediated toxicity [18, 19]. The eﬃciency of each of these
subprocessesiscontrolledbygenes,manyofwhichhavebeen
implicated in association studies (see Table 1).
In genetic association studies, the drive has been to in-
crease statistical power by increasing the numbers of subjects
enrolled. This has resulted in the discovery of important
genes and rare genetic variants, but has not delivered genes
that confer a high degree of risk in the majority of patients.
H o w e v e r ,a si l l u s t r a t e db e l o w ,m o r ec o u l dp e r h a p sb eg a i n e d
by a reanalysis of existing data in relation to other genetic
and risk factor variables that could result in elucidation of
the causes rather than the risks.
2. Methods
Alzheimer’s disease susceptibility genes and risk factors
are stocked in an online database at http://www.polygen-
icpathways.co.uk/alzenvrisk.htm. KEGG pathway analysis of
over400associatedgeneswasperformed[20],andtheresults
of the exercise were posted at http://www.polygenicpath-
ways.co.uk/alzkegg.htm. In these ﬁgures, yellow genes have
been implicated in Alzheimer’s disease and red genes are also
implicated in the herpes simplex life cycle. Other gene-risk
factor relationships were identiﬁed by literature survey. B cell
and T cell epitopes within the beta-amyloid peptide were
identiﬁed using the immune epitope database server http://
tools.immuneepitope.org/main/index.html which predicts
the antigenicity of peptide sequences, based on their charge
and hydrophobicity properties [21]. Sequence comparisons
of the beta-amyloid peptide versus selected bacterial, fungal,
or viral proteomes was performed using the NCBI blast
server [22, 23].
3. Results andDiscussion
3.1. Kegg Pathway Analysis of Alzheimer’s Disease Suscep-
tibilityGenes. Theoverallresultsofthisanalysisareshownin
Table 1. The pathways include many that are relevant to the
known pathologies and risk factors of Alzheimer’s disease,
including the Alzheimer’s disease pathway itself, primarily
related to beta-amyloid and tau processing, but also to
glutamate-related pathways (long-term potentiation and
depression), apoptosis, insulin and diabetes pathways, neu-
rotrophin signalling, oxidative stress (glutathione/oxida-
tive phosphorylation), cerebral hypometabolism (oxidative
phosphorylation, glycolysis and the Krebs cycle), arginine
and proline metabolism (including nitric oxide), and folate,
methionine and homocysteine metabolism, and steroid
hormone synthesis (together with androgen and oestrogen
receptors AR, ESR1, and ESR2). PPAR signalling regulates
many lipoprotein-related genes and cholesterol/lipid path-
ways are dispersed in terpenoid backbone biosynthesis
(FDPS, HMGCR, HMGCS2), steroid hormone biosynthesis
(HSD11B1), steroid biosynthesis (DHCR24, LIPA, SOAT1),
glycerolipid metabolism (ALDH2, LIPC, LPL), and bile acid
biosynthesis (CH25H, CYP46A1) pathways. Immune, com-
plement, and cytokine-related pathways ﬁgure prominently,
as do several pathogen defence pathways including the DNA
sensing retinoic acid inducible gene (RIG-1) pathways that
react to viral DNA/RNA by increasing the expression of
interferons and other antiviral genes, and the Toll receptor
and NOD pattern recognition pathway that control immune
and cytokine networks [24–26]. Glutathione pathways were
also present. Glutathione has potent viricidal and bacterici-
dal properties and is often depleted by infections [27–30].
A number of pathogen entry pathways are also concerned,
and although C. Pneumoniae or C. Neoformans pathways are
not speciﬁcally represented, many of these pathways can be
considered as generic pathways relevant to many bacteria
and other pathogens. The H. Pylori pathway contains only
two genes, IL8 and CSK, but others can be added to this
list including all members of the PI 3-kinase/AKT signalling
network which is activated by the H. pylori protein CagA
[31]o rT o l lr e c e p t o rp a t h w a y st h a ta r ea c t i v a t e db yH. Pylori
heatshock protein, HSP60[32].Similarly, thereis no speciﬁc
HSV-1 viral entry pathway in the KEGG database, but the
virus uses actin pathways, endocytosis, protein processing,
and DNA repair pathways during its life cycle, which are
heavily represented [33].
3.2. Vitamin-A-Related Genes. These were identiﬁed by lit-
erature survey and the most directly relevant are shown
in Table 2. Of particular interest is a close relationship
betweencholesterol/lipoprotein-relatedgenesandvitaminA.
Bothretinolsandcholesterolaretransportedbylipoproteins,
and the clusterin receptor, LRP2/megalin, is a key retinol
entry point. APOE4 is the isoform least able to bind to
retinyl palmitate. ABCA1 is also involved in cholesterol and
retinoltransport.Severalgenes(ALDH2,CYP46A1,GSTM1,
GSTP1, LIPA, LPL, and LRAT) are involved in Vitamin A
metabolism, and 24-s hydroxycholesterol, the product of
CYP46A1, is a ligand for retinoic acid receptors (RARA and
RARG). Retinoid coreceptors and binding partners include
RXRA,ESR1,KLF5NPAS2,NR1H2,PARP1,PIN1,POU2F1,
PPARA, PPARG, THRA, UBQLN1, and VDR. Retinoids
modulate APP processing, via regulation of beta and gamma
secretases while the RIG-1 pathway is crucial in viral defence.ISRN Neurology 3
A large number of genes are also regulated by retinoids or
retinoid receptors.
3.3. The Fox, the Rabbits, Gene, and Environmental Variables.
This is an adaptation of Lees’s classical population genetics
example of the peppered moth, whose dark or pale colouring
confers advantage or disadvantage depending upon the
degree of industrial pollution that covers trees with soot. It
hasservedtoillustratetheconceptofnaturalselectionwhere,
over time, dark genes become more common in polluted
areas, an eﬀect that could eventually lead to speciation [34].
On two islands one covered in snow and the other in
black volcanic ash live an equal number of black and white
rabbits and a family of foxes, who will ﬁnd it easier to
trap the black rabbits on the snowy island and the white
rabbits on the island covered in black ash. Gene association
studies would correctly identify the black and white genes
as being protective or risk promoting depending upon the
environment. The snow, the ash, or the fox, being equally
present on each island, regardless of the toll of dead rabbits,
couldnotbeconsideredasriskfactors.Geneticmeta-analysis
or pooled GWAS data would also rule out any genetic
involvement, leaving no susceptibility genes, no risk factors,
and no cause. However, a GWAS study, apportioning the
genetic data in relation to ash, snow, and fox would be able
to correctly surmise that the white gene is a risk factor on
the ash-covered island, and the black gene a risk factor on
the snowy island, as would have D. R. Lees. Again the fox is
undetectable, being present in all compartments.
Onothersimilarislands,livefurtherpopulationsofblack
and white rabbits with no fox, an equal number of deaths
d u et oo l da g e ,a n dn or e a s o nt oi n v e s t i g a t ee i t h e rg e n e so r
risk factors.However, it is onlyby including this island, again
partitioning GWAS data in relation to all variables, that the
genes, the risk factors, and the cause can be correctly allotted
their respective roles.
In this example, the genes and environmental variable
a r er i s ko rp r o t e c t i v ef a c t o r sf o rt h ec a u s ea sw e l la sf o rt h e
deaths, depending on circumstance. The genes or risk factors
are not killing the rabbits, but are allowing the cause to do
so. Nonstratiﬁed association studies would thus seem to be
ill-suited to ﬁnd important genes, risk factors, or causes, and
the pursuit of greater statistical power may well be futile,
althoughsuchstrategiescanﬁndrarevariantsthatmaycause
disease in a minority of patients, which is evidently useful.
However, for the majority of cases, much could perhaps be
gainedfromareappraisalofexistingdataandbypartitioning
GWASdatainrelationtothemanyknownriskfactorsineach
disease.
The situation is evidently more complex in polygenic
diseases, where hundreds of interacting genes, many risk
factors,andprobablymanycausesarepresent.Thisisalready
appreciated, and several groups have analysed the statistical
problems involved due to the mass of genes and risk factors
[35–37]. However, it is likely that an appropriate selection
of genes and risk factors could markedly aﬀect the degree of
risk. For example, the odds ratio for APOE4 was shown to be
1.67 in Alzheimer’s disease patients without cerebral HSV-1
DNAand16.8inpatientswhereviralDNAwasdetected[38].
The population genetics example, and the discussion below,
suggests that certain susceptibility genes are restricted to risk
factor subsets.
From the above, it would appear that a cause can
be present in equal proportion in control and disease
populations but should be able to produce the pathological
features of the disease, and the disease incidence should be
reduced where the causes are few. A cause can kill regardless
of the genes (black or white) or risk factors (snow or volcanic
ash) but its eﬀects are tempered by a combination of the two
( f o x+s n o w+b l a c kg e n eo rf o x+a s h+w h i t eg e n e= death
a n df o x+s n o w+w h i t eg e n eo rf o x+a s h+b l a c kg e n e ,o rn o
fox and any combination = life). The genes and risk factors
are, however, both able to inﬂuence the cause.
In relation to Alzheimer’s disease, beta-amyloid depo-
sition can be produced by herpes simplex [189–191]o r
chlamydia pneumoniae infection [192, 193], hypercholes-
terolemia (which also causes cholinergic neuronal loss and
memory deﬁcits in rats [194–197]), by or hyperhomocys-
teinaemia, an eﬀect reversed by folate and vitamin-B12
[198], by NGF deprivation [199], by reduced cerebral perfu-
sion(hypoxia, cerebralischaemia, orcarotid arteryocclusion
[200–203]), as well as by experimental diabetes and strep-
tozotocin [204, 205], oestrogen depletion [206], or vitamin
A deﬁciency, which also reduces choline acetyltransferase
activity in the forebrain [207]—all without the aid of any
variant genes, in animal models. While none of the animal
models faithfully reproduce the entire symptomatology of
Alzheimer’s disease, in the clinical setting these risk factors
coexist to varying degrees, rendering the situation rather
more complex.
The risk factors in Alzheimer’s disease include herpes
simplex infection [208] acting in combination with APOE4
[209], C. Pneumoniae [210, 211]o rHelicobacter pylori
infection [212, 213], mild hypercholesterolaemia [214],
but declining cholesterol levels from midlife to late life
[215], atherosclerosis of the carotid arteries, leptomeningeal
arteries, or the circle of Willis, and stroke, leading to cerebral
hypoperfusion [216–219], hyperhomocysteinaemia [220],
type 2 diabetes and modiﬁed insulin metabolism [221], age-
related loss of sex steroid hormones in both women and
men [222], but high total oestradiol levels [223, 224], and
vitaminAdeﬁciency[225].Thesefactorsmaybeconfounded
byinterrelationships,andinsomecasesbythefactthatdeath
due to other causes—for example, atherosclerosis-related
myocardial infarction or stroke may lead to an apparent
paucity of comorbid risk factors in Alzheimer’s disease
groups at later ages.
The genes implicated in Alzheimer’s disease are related
to the herpes simplex life cycle [13, 226], bacterial and
viral entry pathways, viral and pathogen defence (Table 1),
and the immune network [227], cholesterol and lipoprotein
pathways [11, 228], folate and homocysteine pathways [229],
and insulin, or neurotrophin signalling pathways, steroid
metabolism and receptors (Table 1 and 2), and vitamin A
metabolism and function (Table 2).
The genes, risk factors and agents known to increase
beta-amyloid deposition all concur, suggesting that Alz-
heimer’s disease is multifactorial with many foxes, each with4 ISRN Neurology
Table 1: A summary of the KEGG pathway analysis of Alzheimer’s disease susceptibility genes. The number of genes in each pathway is
s h o w ni nb r a c k e t s( s e ehttp://www.polygenicpathways.co.uk/alzkegg.htm for coloured ﬁgures).
Immune system and pathogen defence Pathogen entry pathways Structural and DNA repair
(and HSV-1 pathways)
Cytokine-cytokine receptor interaction
(13) Chagas disease (17) Regulation of actin cytoskeleton (8)
Hematopoietic cell lineage (11) Hepatitis C (13) Endocytosis (8)
Complement and coagulation cascades
(11) Malaria (12) Protein processing in endoplasmic
reticulum (8)
Natural killer cell-mediated cytotoxicity
(10) Amoebiasis (11) Nucleotide excision repair (4)
Chemokine signaling pathway (9) Microbial metabolism in diverse
environments (10) Spliceosome (4)
Phagosome (9) Leishmaniasis (9) DNA replication (3)
Lysosome (8) Viral myocarditis (6) Homologous recombination (3)
T cell receptor signaling pathway (8) Staphylococcus aureus infection (6) RNA transport (2)
Toll-like receptor signaling pathway (8) Bacterial invasion of epithelial cells (4) Mismatch repair (2)
NOD-like receptor signaling
pathway—(7) Pathogenic Escherichia coli infection (3) Base excision repair (2)
Systemic lupus erythematosus (7) Epithelial cell signaling in Helicobacter
pylori infection (2) Apoptosis and oxidative stress
B cell receptor signaling pathway (6) Shigellosis (2) Apoptosis (10)
Graft-versus-host disease (6) Metabolism Drug metabolism cytochrome P450 (6)
Cytosolic DNA-sensing pathway (5) Oxidative phosphorylation (14) Glutathione metabolism (5)
Antigen processing and presentation (5) Arginine and proline metabolism (7) Metabolism of xenobiotics by
cytochrome P450 (5)
Intestinal immune network for IgA
production (5) Glycolysis/gluconeogenesis (5) Peroxisome (3)
Type I diabetes mellitus (5) Valine, leucine, and isoleucine
degradation (4) Drug metabolism—other enzymes (2)
Salivary secretion (5) One carbon pool by folate (3) Signalling pathways
Adipocytokine signaling pathway (5) Terpenoid backbone biosynthesis (3) MAPK signalling (35)
Fc epsilon RI signaling pathway (4) Pyruvate metabolism (3) Calcium signaling pathway (13)
Allograft rejection (4) Citrate cycle (TCA cycle) (3) PPAR signaling pathway (12)
TGF-beta signaling pathway (4) Glycine, serine, and threonine
metabolism (3) Neurotrophin signaling pathway (12)
Autoimmune thyroid disease (4) Protein digestion and absorption (3) Wnt signaling pathway (10)
RIG-I-like receptor signaling pathway (4) Tyrosine metabolism (3) Insulin signaling pathway (9)
Jak-STAT signaling pathway (4) Steroid hormone biosynthesis (3) VEGF signaling pathway (7)
Fc gamma R-mediated phagocytosis (3) Steroid biosynthesis (3) Vascular smooth muscle contraction (6)
Leukocyte transendothelial migration (3) Glycerolipid metabolism (3) Notch signaling pathway (5)
Asthma (3) Porphyrin and chlorophyll metabolism
(3) ABC transporters (5)
Primary immunodeﬁciency (2) Histidine metabolism (2) Renin-angiotensin system (4)
Sphingolipid metabolism (2) Cardiac muscle contraction (4)
Cysteine and methionine metabolism (2) mTOR signaling pathway (3)
Purine metabolism (2) ErbB signaling pathway (3)
Tryptophan metabolism (2) Aldosterone-regulated sodium
reabsorption (3)
Lysine degradation (2) Progesterone-mediated oocyte
maturation (3)
Primary bile acid biosynthesis (2) GnRH signaling pathway (2)
Hedgehog signaling pathway (2)ISRN Neurology 5
Table 2: The relationships of Alzheimer’s disease susceptibility genes with vitamin A. NF = none found.
Gene Name Relationships with vitamin A
Transport and entry
ALB Albumin Together with retinol binding protein forms the retinol
transporter [39]
APOE Apolipoprotein E Expression regulated by LXR/RXR dimers [40]
Involved in retinyl palmitate transport [41]
TTR Transthyretin (prealbumin,
amyloidosis type I) Carrier protein for the retinol binding protein [42]
APOA1 Apolipoprotein A-I RORA target [43]: associates with transthyretin in
plasma [44]
HSPG2 Perlecan: (heparan sulfate
proteoglycan 2) Binds to transthyretin [45]
A2M Alpha-2-macroglobulin Synthesis decreased in vitamin-A- deﬁcient rats [46]
ABCA1
ATP-binding cassette,
subfamily A (ABC1),
member 1
22R-hydroxycholesterol and 9-cis-retinoic acid induce
ABCA1 expression and cholesterol eﬄux in brain cells
and decrease Beta-amyloid secretion [47]. Involved in
retinol and alpha- and gamma-tocopherol transport
[48, 49]
CLU Clusterin (APOJ) LRP2
ligand
The clusterin promoter contains a RARE sequence:
Expression is suppressed by all-trans-retinoic acid [50].
Vitamin A deﬁciency increases clusterin expression in
sertoli cells [51]
LRP2
Low density
lipoprotein-related protein
2( c l u s t e r i nr e c e p t o r )
Mediates the endocytosis of retinol via binding to
retinol binding proteins and transthyretin [52, 53]
LRPAP1
Low density lipoprotein
receptor-related protein
associated protein 1
Regulates the uptake of retinol by LRP2 [54]
Metabolism
ALDH2 Aldehyde dehydrogenase 2
family (mitochondrial)
Exhibits low NAD(+)-dependent retinaldehyde activity
[55]: regulated by RARB [56]
CYP46A1
Cytochrome P450, family
46, subfamily A,
polypeptide 1
Synthesises 24-S hydroxycholesterol, a ligand for RARA
and RARG [57]
GSTM1 Glutathione S-transferase
M1
Weakly catalyses the enzymic isomerization of
13-cis-retinoic acid to all-trans-retinoic acid [58]
GSTP1 Glutathione S-transferase
pi
Catalyses the enzymic isomerization of 13-cis-retinoic
acid to all-trans-retinoic acid [58]
LIPA
Lipase A, lysosomal acid,
cholesterol esterase
(Wolman disease)
Metabolises carotenoid mono- and diesters providing a
source of free carotenoids in the gut [59]
LPL Lipoprotein lipase Metabolises retinyl esters [60]. RORA target [61]
LRAT
Lecithin retinol
acyltransferase
(phosphatidylcholine—
retinol
O-acyltransferase)
Lecithin retinol acyltransferase
(phosphatidylcholine—retinol O-acyltransferase)
MEF2A Myocyte enhancer factor
2A
Regulates beta-carotene 15,15 -monooxygenase 1
which cleaves beta-carotene to all-trans retinal and is
the key enzyme in the intestinal metabolism of
carotenes to vitamin A [62]
Receptors, coreceptors and receptor binding partners
CHD4 Chromodomain helicase
DNA binding protein 4 Binds to RORG [63]
ESR1 Estrogen receptor 1 Dimerises with RAR and RXRA [52]
KLF5 Kruppel-like factor 5
(intestinal) Binds to RARA [64]6 ISRN Neurology
Table 2: Continued.
Gene Name Relationships with vitamin A
NPAS2 Neuronal PAS domain
protein 2
RAR alpha and RXR alpha bind to CLOCK and NPAS2
[65]. RORA target [66]
NR1H2
Nuclear receptor subfamily
1 ,g r o u pH ,m e m b e r2 :l i v e r
Xr e c e p t o rb e t a
LXRs form obligate heterodimers with retinoid X
receptors RARA, RXRA, RXRB, RXRG (Entrez gene)
PARP1
Poly (ADP-ribose)
polymerase family, member
1
Interacts with RARB [67]
PIN1
Protein (peptidylprolyl
cis/trans isomerase)
NIMA-interacting 1
RARalpha directly interacts with Pin1. Overexpression
of Pin1 inhibits ligand-dependent activation of
RARalpha [68]
POU2F1 POU class 2 homeobox 1 Binds to RXR [69]
PPARA
Peroxisome
proliferator-activated
receptor alpha
Dimerises with RXRA and RXRG receptors [70]
PPARG
Peroxisome
proliferator-activated
receptor gamma
Dimerises with RXRA receptors [71]
RXRA Retinoid X receptor, alpha Retinoic acid receptor
THRA
Thyroid hormone receptor,
alpha (erythroblastic
leukemia viral (v-erb-a)
oncogene homolog, avian)
Dimerises with RXRA [72]
UBQLN1 Ubiquilin 1 Binds to retinoic acid receptor alpha [73]
VDR
Vitamin D
(1,25-dihydroxyvitamin
D3) receptor
Heterodimerises with RXR and RARG [74]
APP and tau processing
APP
Amyloid beta (A4)
precursor protein
(peptidase nexin-II,
Alzheimer disease)
A gamma 57 gamma secretase cleavage product
suppresses retinoid signalling [75]
BACE1 Beta-site APP-cleaving
enzyme 1 Regulated by all-trans-retinoic acid [76]
NCSTN Nicastrin Blocks the eﬀects of retinoic acid on neurogenesis [77]
PSEN1 Presenilin 1 (Alzheimer
disease 3)
Regulated by and regulates the eﬀects of retinoic acid
on neuronal diﬀerentiation [78, 79]
PSEN2 Presenilin 2 (Alzheimer
disease 4) Activated by all-trans-retinoic acid in osteoblasts [80]
CDK5 Cyclin-dependent kinase 5 Activated by retinoic acid [81]
GSK3B Glycogen synthase kinase 3
beta
SH-SY5Y cells diﬀerentiate to neuron-like cells when
treated with Retinoic acid/BDNF leading to increases in
tau and tau phosphorylation, mediated primarily by
GSK3B [82]: GSK3B inhibitors inhibit
RARbeta-induced adipogenesis in mouse embryonic
stem cells [83].
MAPT Microtubule-associated
protein tau
Phosphorylation of tau at the 12E8 (Ser-262/Ser-356)
epitope decreased in retinoic acid treated cells:
increased at Ser-195/Ser-198/Ser-199/Ser-202) and
(Ser-396/Ser-404) [84]
Viral and bacterial defence RIG-1, PKR, NOD and
Toll receptor signalling
CARD8 Caspase recruitment
domain family, member 8 NF
CD14 CD14 molecule Expression regulated by retinoids [85]: binds to H.
Pylori lipopolysaccharide [86].ISRN Neurology 7
Table 2: Continued.
Gene Name Relationships with vitamin A
CD86 CD86 molecule Expression modulated by and the viral DNA minic
polyriboinosinic:polyribocytidylic acid [87]
CST3 Cystatin C NF antimicrobial peptide [88]
DEFB122 Defensin, beta 122:
Antimicrobial peptide NF
EIF2AK2
Eukaryotic translation
initiation factor 2-alpha
kinase 2: (PKR activated by
viral DNA)
Upregulated by retinoic acid in HL-60 leukemia cells
[89]
GBP2 Guanylate binding protein
2, interferon inducible NF
MEFV Mediterranean fever NF
MPO Myeloperoxidase Antimicrobial peptide [88], expression regulated by
RXR/PPAR gamma heterodimer [90]
PIN1
peptidylprolyl cis/trans
isomerase,
NIMA-interacting 1
Binds to and negatively regulates IRF3 [91]
TF Transferrin
Antimicrobial peptide [88]. Vitamin A deﬁciency is
associated with modiﬁed iron homeostasis that can be
reversed by retinoid supplementation, TF contains a
peroxisome proliferator-activated receptor-retinoic
acid X receptor heterodimer binding site [92]
TRAF2 TNF receptor-associated
factor 2
Infection with RNA viruses activates the cytoplasmic
retinoic acid-inducible gene-I (RIG-I) pathway which
activates transcription factor IRF-3 which in turn
induces many antiviral genes. It also induces apoptosis
via TRAF2 [25]
TLR4 Toll-like receptor 4 Expression suppressed by retinoic acid [93]
PVRL2
Poliovirus receptor-related
2 (herpesvirus entry
mediator B)
NF: herpes simplex receptor
ZBP1
Z-DNA binding protein 1:
DNA-dependent activator
of interferon regulatory
factors
NF
Cholesterol lipoprotein networks and lipid rafts
ABCA1 Retinol transporter (see above)
ABCG1
ATP-binding cassette,
subfamily G (WHITE),
member 1
Expression regulated by 9-cis retinoic acid and
22-hydroxycholesterol [94]
APOA5 Apolipoprotein A-V
Regulated by RORA [95]. APOA5 polymorphisms
modify lipoprotein bound retinyl palmitate
concentrations [96]
APOC2 Apolipoprotein C-II Expression regulated by 9-cis-retinoic acid [97].
APOC3 Apolipoprotein C-III RORA target [43]
APOC4 Apolipoprotein C-IV Expression regulated by RXR ligands [98]
APOD Apolipoprotein D Expression regulated by RARA [99]
CETP Cholesteryl ester transfer
protein, plasma
Expression induced by 9-cis retinoic acid (RXR agonist)
[100]
FDPS
Farnesyl diphosphate
synthase (farnesyl
pyrophosphate synthetase,
dimethylallyltranstrans-
ferase,
geranyltranstransferase)
Activated by the LXR/retinoid X receptor dimer [101]8 ISRN Neurology
Table 2: Continued.
Gene Name Relationships with vitamin A
LPA Lipoprotein, Lp(a) Isotretinoin reduces LPA serum levels [102]
LDLR
Low-density lipoprotein
receptor (familial
hypercholesterolemia)
NF
LRP1
Low-density
lipoprotein-related protein
1 (alpha-2-macroglobulin
receptor)
NF
LRP2 See above (retinol receptor)
LRP6 Low-density lipoprotein
receptor-related protein 6 Expression induced by retinoic acid [103]
LRP8
Low-density lipoprotein
receptor-related protein 8,
apolipoprotein e receptor
NF
NPC1 Niemann-Pick disease, type
C1 NF
NPC2 Niemann-Pick disease, type
C2 NF
OLR1
Oxidized low-density
lipoprotein (lectin-like)
receptor 1
NF
RFTN1 Raftlin, lipid raft linker 1 NF
SOAT1 sterol O-acyltransferase 1:
cholesterol acyltransferase NF
SREBF1
Sterol regulatory element
binding transcription
factor 1
Liver X receptor/RXR target [104]
VLDLR Very-low-density
lipoprotein receptor
All-trans retinoic acid increases expression in
adenocarcinoma cells [105]
Chemokines and cytokines and inﬂammation
AGER Advanced glycosylation end
product-speciﬁc receptor
Expression upregulated by retinol and vitamin A
[106, 107]
ALOX5 Arachidonate
5-lipoxygenase RORA target [108]
CCL2 Chemokine (C-C motif)
ligand 2
All-trans-retinoic acid suppresses bacterial
lipopolysaccharide-induced expression and release in
astrocytes [109]
CCL3 Chemokine (C-C motif)
ligand 3 See CCL2 above
CCR2 Chemokine (C-C motif)
receptor 2 Expression regulated by 9-cis-Retinoic acid [110]
IL10 Interleukin 10 All trans-retinoic acid increases IL10 production in
monocytes and macrophages [111]
IL18
Interleukin 18 (interferon-
gamma-inducing
factor)
Diﬀerentiation of SH-SY5Y neuroblastoma cells by
all-trans retinoic acid activates IL18 [112].
IL1A Interleukin 1, alpha Retinoic acid decreases expression in thymic epithelial
cells [113]
IL1B Interleukin 1, beta
Intraperitoneal retinoic acid reduces IL-1β,I L - 6a n d
TNFα mRNA levels in the spinal cord after injury
[114]. All-trans-retinoic acid increases IL1B expression
in human aortic smooth muscle cells [115]
IL33 Interleukin 33 NF
IL6 Interleukin 6 (interferon,
beta 2)
Retinoic acid increases expression in thymic epithelial
cells [113].ISRN Neurology 9
Table 2: Continued.
Gene Name Relationships with vitamin A
IL8 Interleukin 8
Retinoid administration decreases polymorphonuclear
neutrophilic leukocyte accumulation in mammary
alveoli activated by lipopolysaccharide, and decreases
IL-8 serum levels [116]
IL1RN interleukin 1 receptor
antagonist
Retinoic acid enhances IL-1 beta and inhibited IL-1ra
production in 4beta phorbol 12beta-myristate-13alpha
acetate - and lipopolysaccharide-activated human
alveolar macrophages [117].
PTGS2
Prostaglandin-
endoperoxide synthase 2
(prostaglandin G/H
synthase and
cyclooxygenase)
Suppressed by RARB [118]
TGFB1 Transforming growth
factor, beta 1 Repressed by RXRA.PPARG dimers [119]
TNF
T u m o rn e c r o s i sf a c t o r
(TNF superfamily, member
2)
LPS from bacterial pathogens activates Retinoic
inducible gene RIG-I which plays a key role in the
expression of TNF-alpha in macrophages in response to
LPS stimulation [120]
FAS Fas (TNF receptor
superfamily, member 6)
Retinoic acid increases the expression of FAS in
adipocytes: all-trans retinoid acid reduces FAS
expression in HELA cells
Complement and immune system
C4A Complement component
4A (Rodgers blood group)
Complement C4 levels correlate with those of retinol in
plasma [121]
C4B Complement component
4B (Chido blood group) See above
CFH Complement factor H Expression controlled by RAR beta [122]
CLU Clusterin See above
CR1
Complement component
(3b/4b) receptor 1 (Knops
blood group)
NF
CRP C-reactive protein,
pentraxin related
Serum CRP levels negatively correlate with vitamin A
levels [123]
CD33 CD33 molecule NF
CD36
CD36 molecule
(thrombospondin
receptor)
RORA target [61]
HLA-A Major histocompatibility
complex, class I, A
Upregulated by diﬀerentiation of teratoma cells into
neuronal cells by retinoic acid [124]
HLA-A2 Major histocompatibility
complex, class I, A2
Upregulated by interferon alpha-2b and retinoic acid
combined treatment in cervical cancer cells [125]
MICA
MHC class I
polypeptide-related
sequence A
Expression upregulated by retinoic acid in hepatic
carcinoma cells [126]
Oestrogen and androgen related
AR
Androgen receptor
(dihydrotestosterone
receptor; testicular
feminization; spinal and
bulbar muscular atrophy;
Kennedy disease)
ESR1 See above
ESR2 Estrogen receptor 2 (ER
beta)
9-cis retinoic acid stimulates expression in breast
cancer cells [127]10 ISRN Neurology
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CYP19A1
Cytochrome P450, family
19, subfamily A,
polypeptide 1: aromatase:
estrogen synthase
Activated by RORA [128]
HSD11B1 Hydroxysteroid (11-beta)
dehydrogenase 1 NF
Growth factor networks
BDNF Brain-derived neurotrophic
factor
Expression regulated by RARalpha/beta and vitamin A
[129, 130], but all-trans retinoic acid reduces BDNF
and TrkB gene expression in SH-SY5Y cells [131]
CSK C-src tyrosine kinase CSK negatively regulates RAR functions in relation to
neurite diﬀerentiation [132]
FGF1 Fibroblast growth factor 1
(acidic)
Protects ﬁbroblasts from apoptosis induced by retinoid
CD437 [133]
GAB2 GRB2-associated binding
protein 2
Gab2 silencing results in hypersensitivity to retinoic
acid -induced apoptosis in neuronal cells [134]
IGF1 Insulin-like growth factor 1
(somatomedin C)
Pulmonary expression reduced in RORalpha knockout
mice [135]
NTRK1 Neurotrophic tyrosine
kinase, receptor, type 1
Retinoic acid restores adult hippocampal neurogenesis
and reverses spatial memory deﬁcit in
vitamin-A-deprived rats, partly by upregulating
NTRK1 (TrkA) [136]
NTRK2 Neurotrophic tyrosine
kinase, receptor, type 2
All-trans retinoic acid reduces BDNF and TrkB gene
expression in SH-SY5Y cells [131]
VEGFA vascular endothelial growth
factor A Expression regulated by retinoid acid [137]
Other signalling
DKK1 Dickkopf homolog 1
(Xenopus laevis) Expression regulated by retinoic acid in stem cells [103]
DPYSL2 Dihydropyrimidinase-like 2 Upregulated in cortex and hippocampus by Vitamin A
depletion [138]
Homocysteine and methionine metabolism
BLMH Bleomycin hydrolase Hydrolyses homocysteine thiolactone [139]
CBS Cystathionine-beta-
synthase
Converts homocysteine to cystathionine suppressed by
all-trans-retinoic acid [140]
MSRA methionine sulfoxide
reductase A
Regulated by retinoic acid via two promoters including
RARA [141]
MTHFD1L
Methylenetetrahydrofolate
dehydrogenase (NADP+
dependent) 1-like
NF
MTHFR
5,10-
methylenetetrahydrofolate
reductase (NADPH)
Methylenetetrahydrofolate reductase activity is
s u p p r e s s e di nr e t i n o l - f e dr a t s[ 142]
MTR
5-methyltetrahydrofolate-
homocysteine
methyltransferase
In rats, a retinol-rich diet enhances the
folate-dependent oxidation to CO2 of formate and
histidine. The activity of hepatic
methylenetetrahydrofolate reductase, which regulates
liver folate metabolism, is suppressed, leading to
decreased 5-methyltetrahydrofolate synthesis [142]
MTRR
5-methyltetrahydrofolate-
homocysteine
methyltransferase reductase
NF
PON1 Paraoxonase 1 Hydrolyses homocysteine thiolactone [143]: vitamin A
deﬁciency reduced serum PON1 activity in rats [144].ISRN Neurology 11
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Oxidative stress, Iron and mitochondria
COX1 Mitochondrially encoded
cytochrome c oxidase I
9-cis retinoic acid treatment increases mitochondrial
DNA transcription, including ND1, ND6, and COX1
[145]
COX2 Mitochondrially encoded
cytochrome c oxidase II Expression increased by all-trans retinoic acid [146]
GAPDH
Glyceraldehyde-3-
phosphate
dehydrogenase
Retinoic acid target [147]
GSTM3 Glutathione S-transferase
M3 (brain) Contains a retinoid X receptor-binding site [148]
HBG2 Hemoglobin, gamma G Vitamin A increases haemoglobin concentrations in
children [149]
HFE hemochromatosis Neuroblastoma cells carrying the C282Y HFE variant
do not diﬀerentiate when exposed to retinoic acid [150]
HMOX1 Heme oxygenase
(decycling) 1
The increase in the expression of heme oxygenase-1
and the growth arrest and DNA damage-inducible
transcription factor 153 caused by reactive oxygen
species is blocked by aRARalpha-speciﬁc antagonist
AGN194301 in retinal epithelial cells [151]
ND1 NADH dehydrogenase
subunit 1
9-cis retinoic acid treatment increases mitochondrial
DNA transcription, including ND1, ND6, and COX1
[145]
ND4 NADH dehydrogenase
subunit 4
Upregulated by all-trans retinoic acid in neutrophils
[152]
ND6 NADH dehydrogenase
subunit 6
9-cis retinoic acid treatment increases mitochondrial
DNA transcription, including ND1, ND6, and COX1
[145]
NFE2L2 Nuclear factor
(erythroid-derived 2)-like 2
Inhibited by retinoic acid via RARalpha resulting in
lack of expression of Nrf2 target genes [153]i n
mammary cells, but retinoic acid and
12-O-tetradecanoylphorbol acetate are also able to
induce Nrf2 and its target gene NAD(P)H quinone
oxidoreductase 1 in the SH-SY5Y neuroblastoma cell
line [154].
NOS1 Nitric oxide synthase 1
(neuronal) Expression regulated by retinoic acid [84]
NOS2 Nitric oxide synthase 2,
inducible Ditto
NOS3 Nitric oxide synthase 3
(endothelial cell) Ditto
NQO1 NAD(P)H dehydrogenase,
quinone 1
Retinoic acid (RA) and 12-O-tetradecanoylphorbol
acetats are able to induce Nrf2 and its target gene
NAD(P)H quinone oxidoreductase 1 in the SH-SY5Y
neuroblastomacell line [154]
SOD2 Superoxide dismutase 2,
mitochondrial
All-trans-retinoic acid induces manganese superoxide
dismutase in a human neuroblastoma cell line [155]
PCK1 Phosphoenolpyruvate
carboxykinase 1 (soluble)
Three RXR-binding elements (retinoic acid response
element (RARE)1/PCK1, RARE2, and RARE3/PCK2)
are located in the promoter of Pck1 [156]
PON2 Paraoxonase 2 NF
PON3 Paraoxonase 3 NF
TFAM Transcription factor A,
mitochondrial Levels are increased by vitamin A [157]12 ISRN Neurology
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Heat shock
DNAJC28 DnaJ (Hsp40) homolog,
subfamily C, member 28 NF
HSPA1B Heat shock 70kDa protein
1B NF
HSPA5
Heat shock 70kDa protein
5 (glucose-regulated
protein, 78kDa)
Endoplasmic reticulum stress is increased in
hepatocarcinoma cells by all-trans retinoic acid,
characterised by increased expression of HSPA5
(grp78), GADD153, and XBP1[158]
Monoamine networks
ADRB1 Adrenergic, beta-1-,
receptor RARA target [159]
ADRB2 Adrenergic, beta-2-,
receptor, surface Expression regulated by all-trans retinoic acid [160]
COMT Catechol-O-
methyltransferase Expression stimulated by all-trans retinoic acid [161]
PNMT Phenylethanolamine
N-methyltransferase
Retinoic acid diﬀerentiates embryonic carcinoma cells
into neuronal cells, 70% of which stain for tyrosine
hydroxylase, dopamine beta-hydroxylase, and
phenylethanolamine N-methyltransferase [162].
Cholinergic
CHAT Choline acetyltransferase Expression controlled by retinoic acid [163]
CHRNA3 Cholinergic receptor,
nicotinic, alpha 3 Expression increased by retinoid acid [164]
CHRNA4 Cholinergic receptor,
nicotinic, alpha 4 Expression decreased by retinoic acid [164]
CHRNB2 Cholinergic receptor,
nicotinic, beta 2 (neuronal) Expression increased by retinoid acid [164]
Neuropeptide
GRN Granulin All-trans retinoic acid increases expression in myeloid
cells [165]
Adhesion and proteoglycans
ACAN Aggrecan Expression modulated by 13-cis retinoic acid in
ﬁbroblasts [166]
ICAM1
Intercellular adhesion
molecule 1 (CD54), human
rhinovirus receptor
All-trans retinoic acid downregulates ICAM1
expression in bone marrow stromal cells [167]
Structural, dynamins, and kinesins
COL11A1 Collagen, type XI, alpha 1 Expression controlled by all-trans-retinoic acid [168]
DSC1 Desmocollin 1 Retinoic acid decreases expression in oral keratinocytes
[169]
LMNA Lamin A/C (nuclear) Promoter contains a retinoic acid-responsive element
(L-RARE) [170]
Ubiquitin
UBD Ubiquitin D
All-trans retinoic acid activated the
ubiquitin/proteasome pathway in human acute myeloid
leukemia cell lines [171]
UBE2I
Ubiquitin-conjugating
enzyme E2I (UBC9
homolog, yeast)
See above
DNA repair
XRCC1
X-ray repair
complementing defective
repair in Chinese hamster
cells 1
N-[4-hydroxyphenyl] retinamide induces apoptosis in
bladder cancer cell line and downregulates XRCC1
[172]ISRN Neurology 13
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Cell cycle and tumour
CDC2 Cell division cycle 2, G1 to
S ,a n dG 2t oM Activated by retinoic acid [173]
Miscellaneous metabolism
ACAD8
Acyl-coenzyme A
dehydrogenase family,
member 8
Catalyzes the dehydrogenation of acyl-CoA derivatives
in the metabolism of fatty acids or branch chained
amino acids. The encoded protein is a mitochondrial
enzyme that functions in catabolism of the
branched-chain amino acid valine.
ALDH18A1 Aldehyde dehydrogenase 18
family, member A1
NF the encoded protein catalyzes the reduction of
glutamate to delta1-pyrroline-5-carboxylate, a critical
step in the de novo biosynthesis of proline, ornithine
and arginine.
ARSA
Arylsulfatase A: hydrolyzes
cerebroside sulfate to
cerebroside and sulphate
Increased urinary excretion of both arylsulfatases A and
B is increased in cases of severe vitamin A deﬁciency
coupled with malnutrition [174]
ELAVL4
ELAV (embryonic lethal,
abnormal vision,
drosophila)-like 4 (Hu
antigen D)
Inhibition reduces retinoic acid-induced neuronal
diﬀerentiation of mouse embryonal carcinoma P19
cells [175]
SGPL1 Sphingosine-1-phosphate
lyase 1
Treatment of F9 embryonal carcinoma cells with
retinoic acid induces diﬀerentiation to primitive
endoderm (PrE). This eﬀect is attenuated by SGPL1
knockout [176].
Miscellaneous
CELF2 CUGBP, Elav-like family
member 2 Splicing regulated by retinoic acid [177]
CUBN Cubilin (intrinsic
factor-cobalamin receptor) Expression regulated by all-trans-retinoic acid [178]
F13A1 Coagulation factor XIII, A1
polypeptide
Vitamin A reduces factor XIII levels in rats fed an
atherogenic diet [179].
HHEX Hematopoietically
expressed homeobox
All-trans retinoic acid enhances expression in normal
and tumorous mammary tissue [180]
NEDD9
Neural precursor cell
expressed, developmentally
downregulated 9
Downstream target of all-trans retinoic acid and its
receptors in the human SH-SY5Y neuroblastoma cell
line [181]
RELN Reelin Retinoic acid-induced diﬀerentiation of NT2 cells to
hNT neurons increases reelin expression [182].
RNR1 RNA, ribosomal 1 NF
RPS3A Ribosomal protein S3A Downregulated by retinoid-induced diﬀerentiation of
HL-60 cells [183]
RUNX1
Runt-related transcription
factor 1 (acute myeloid
leukemia 1; aml1
oncogene)
RUNX1 knockdown inhibits retinoid-induced
diﬀerentiation of HL-60 myeloid leukaemia cells [184].
SEPT3 Septin 3 Expressed in SH-SY5Y, after retinoic acid-induced
diﬀerentiation [185]
SNCA
Synuclein, alpha (non-A4
c o m p o n e n to fa m y l o i d
precursor)
Vitamin A, beta-carotene and coenzyme Q10 inhibit
the formation of synuclein ﬁbrils [186]
SYN3 Synapsin III Synapsins including SYN3 are upregulated by retinoic
acid-induced diﬀerentiation of NTera-2cl.D1 cells [187]
TARDBP TAR DNA binding protein NF
VCP Valosin-containing protein
Retinoic acid receptor responder (RARRES1) regulates
VCP expression in human prostatic epithelial cells
[188]14 ISRN Neurology
their respective genes and risk factors, any of which can lead
to beta-amyloid deposition in multifarious ways. Each risk
factor can act independently of any gene or other risk factor
variant, in animal models—as with the fox. This in turn
might suggest that it is not the risk promoting polymor-
phisms in the Alzheimer’s disease patients that are crucial,
as the risk factors can in any case promote beta-amyloid
deposition, but the equivalent polymorphisms in the control
group, that are providing protection; a subtle distinction
that awaits characterisation of the functional eﬀects of many
diﬀerentgenevariants.Thereasoningalsosuggeststhatbeta-
amyloid deposition is the consequence and not the cause
of the many factors able to promote Alzheimer’s disease.
Anoxia, ischaemia, hypoglycaemia, hypercholesterolaemia,
andvitaminAdeﬁciencyareallabletokillneurones,insome
cases including cholinergic neurones, without the aid of beta
amyloid.
3.4. Low Incidence of Alzheimer’s Disease and Protective Fac-
tors. In relation to Alzheimer’s disease, there is an island
where longevity is increased, related to the nun study [231–
234].Nunsdonothavechildren,(thenumberofpregnancies
is a risk factor in Alzheimer’s disease [235]), do not consume
high concentrations of saturated fats (low cholesterol), and
are unlikely to have sexually transmitted diseases or viral
and other common pathogen diseases vectored by childhood
infections (Herpes and chlamydia, inter alia). Their vitamin
A levels and general health are sustained by a healthy diet,
regular ﬁsh on Fridays, and exercise.
There are few strategies that have been shown to reduce
the severity of Alzheimer’s disease, once established. It
has, however, been shown that Helicobacter pylori elimi-
nation increases the cognitive abilities and the lifespan of
Alzheimer’s disease patients [236]. In addition, two separate
case reports have shown complete reversal of dementia in
two patients diagnosed with Alzheimer’s disease, by identi-
ﬁcation and eradication of the fungal pathogen Cryptococcus
Neoformans [237, 238].The TNF antagonist, etanercept, has
also been reported to produce a striking remedial eﬀect
on symptomatology, following perispinal application [239].
However, the use of TNF antagonists is also associated with
anincreasedincidenceofopportunisticbacterial,fungal,and
viral infestations, including cytomegalovirus, and crypto-
coccal infections [240], perhaps a contraindication for their
prolonged use.
Anumberofepidemiologicalstudieshaveshownthatthe
incidence of Alzheimer’s disease can be reduced, although,
once the disease is established, there is little evidence for
any curative eﬀects of any treatment other than the above.
These protective factors are in most cases the obverse of the
risk factors and include diets rich in ﬁsh or polyunsaturated
fatty acids [241, 242], the Mediterranean diet [243] and the
use of statins [244], which are counter to the eﬀects of high
cholesterol. A diet rich in fruit and vegetables is associated
with reduced dementia incidence [245] and is able to sustain
Vitamin A levels and reduce homocysteine levels in the
elderly population [246]. High folate intake, which reduces
homocysteine levels [247], and the use of nonsteroidal anti-
inﬂammatories have also been reported to reduce risk [248].
Again these are related to the risk factors and to the genes,
which may condition their success (cf. Vitamin E).
3.5. Relevance of These Factors to the Genes Identiﬁed in
Genome-Wide Association Studies. Four major genes have
been discovered prior to and from GWAS studies, APOE4,
clusterin, complement receptor 1, and PICALM [6, 249].
The close relationships between these genes and herpes
simplex infection have been the subject of a previous article
[226]. APOE4 also favours the binding of C. Pneumoniae
elementary bodies to host cells [250]. It is also a risk factor
forhypercholesterolaemia,perse[251],andforcarotidartery
atherosclerosis in men with diabetes [252]. APOE4 is also
the isoform least able to promote lipid eﬄux from neuronal
cells [253], a factor that may enhance the cholesterol
dependent cleavage of beta-amyloid by beta and gamma
secretase [254]. It is also the least able isoform binding the
vitamin A precursor retinyl palmitate [255] (see below).
Complement receptor 1 is a pathogen receptor for both
herpes simplex [256], and C. Neoformans [257] and also for
the atherogenic pathogen, P. Gingivalis [258], a key cause of
periodontitis/gum disease, which has also been implicated as
ar i s kf a c t o ri nd e m e n t i a[ 259]. Both Helicobacter pylori and
C. Pneumoniae [260] use the mannose-6-phosphate IGF2
receptor (inter alia) for entry. This binds to clusterin and its
endocytosis is controlled by PICALM [226]. PICALM (phos-
phatidylinositol binding clathrin assembly protein), as its
name implies, is involved in clathrin-mediated endocytosis
[261], a process used by C. Pneumoniae to gain cellular entry
[262], for the internalisation of herpes simplex glycoprotein
D[ 263] or the cytomegalovirus chemokine receptor [264]
and for the uptake of outer membrane vesicles from certain
strainsofH.pylori,intogastricepithelialcells[265].Clathrin
also associates with HHV-6 virions [266]. Clusterin is an
inhibitor of the membrane attack complex that is inserted
into microbial membranes causing death by lysis [267]. It is
also a ligand for the retinol/lipoprotein receptor LRP2 [268],
and the gene contains a retinoid response element (Table 2).
Thus it would seem that the key role of these genes may be
related to their ability to target multiple aspects of diverse
risk factor networks.
3.6. Relationships between Risk Factors and a Key Role for
HerpesSimplexActivation(Figure1). Hypercholesterolaemia
can evidently be related to other dietary risk factors such as
saturated fat consumption, and to atherosclerosis. Docos-
ahexaenoic acid increases total plasma cholesterol levels
in hymans, but only in APOE4 carriers, an eﬀect that
may negate the cardioprotective eﬀects of ﬁsh oil supple-
mentation [269]. Helicobacter pylori infection also causes
malabsorption of vitamin B12 and folate, leading to
increased homocysteine levels, that can be restored by
H. pylori eradication [270]. Homocysteine metabolism is
also related to glutathione synthesis via the transsulfuration
pathway (homocysteine→cysteine→glutathione). Increased
levels of homocysteine and reduced levels of glutathione in
Alzheimer’s disease suggest impairments in the transsulfu-
ration pathway [271] .G l u t a t h i o n ei sap o t e n ta n t i v i r a la n dISRN Neurology 15
Immune system
CR1, C4A, CLU,
FCER1G, HLA-A, HLA-
DRB1, IL1B, TAP2
Other infections
CARD8, CD14,
CR1, CLU, DEFB122
, PICALM
Atheroclerosis
ABCA1, APOA1, APOE,
CLU, LRP1, LRP2,
LRP8, LDLR.
VLDLR
Cerebral
hypoperfusion
COX1, DLD, GAPDH,
ND1, ND3
Autoantibodies
Aβ, NFTs, NGF,
cholinergic
neurones
Herpes simplex
APOE, APP, CR1,
EIF2AK2, IDE,
LMNA, PICALM,
PVRL2
Vitamin A
ABCA1, ALB,
APOE,CYP46A1,
LRAT, LRP2 RXR, TTR Homocysteine
BLMH, CBS, GSTPI,
MTR, MTHFR,
PON1
Glutathione
CBS, GSTM1,
GSTM3, GSTO1,
GSTT1, NFE2L2
Cholesterol
ABCA1, APOE,
CETP, CH25H,
HMCGR, HMGCS2,
SREBF1
Oestrodiol
CYP19A1, ESR1,
ESR2, HSD11B1
NGF
GSK3B, NTRK1,
NTRK2, PIK3R1,
SOS2
Aβ
Figure 1: An environmental risk factor-gene interactome in Alzheimer’s disease. Risk factors diminished in Alzheimer’s disease (vitamin
A deﬁciency, NGF levels, immune competence, and glutathione depletion) are shown in blue and those increased in red. Solid
lines indicate a positive, and dashed or dotted lines a negative eﬀect of risk factor X on risk factor Y. All risk factors feed into
increased beta-amyloid deposition. A selection of susceptibility genes relevant to each process is shown (see Table 2 and http://www
.polygenicpathways.co.uk/alzpolys.html.
bactericidal agent with eﬀects targeted at herpes simplex
and C. Pneumoniae,i n t e ra l i aboth of which also diminish
glutathione levels in infected cells [27, 272, 273]. H. pylori
expresses an enzyme, gamma-glutamyltranspeptidase that
enables it to metabolise the host’s extracellular glutamine
and glutathione which are hydrolysed to glutamate, which
is fed into the H. pylori Krebs cycle, resulting in diminished
glutathione levels that can be restored by H. pylori elimina-
tion [27, 273]. Glutathione levels are reduced in Alzheimer’s
disease and many others [274].
Inbothcoronaryarterydiseaseandcarotidarteryathero-
sclerosis, high plasma levels of homocysteine are positively
correlated with C. Pneumoniae seropositivity suggesting a
role for the bacterium in promoting high homocysteine
levels. [275, 276]. Indeed carotid artery atherosclerosis is
correlated with antibodies to C. Pneumoniae,a n dt oal e s s e r
extent with antibodies to H. pylori, but in this case, only in
individuals with low social status [277].
T h eg r o w t ho fC .N e o f o r m a n si sa t t e n u a t e db yd i e t h y l -
stilbestrol and oestradiol but not by progesterone or testos-
terone [278]. Helicobacter pylori adsorbs a number of
steroids including pregnenolone and two androgens (dehy-
droepiandrosterone and epiandrosterone and 3-hydroxy-
lated oestrogens (oestrone and oestradiol). These are gluco-
sylated and the glucosyl-steroid hormone derivatives used as
membrane lipid components [279]. Oestradiol, androstene-
dione, and progesterone are all able to inhibit the growth of
H. pylori [280].
These complex interactions, of which there are likely
many more, suggest that in addition to epistasis and gene-
environment interactions, environment-environment inter-
actionshavetobefactoredintoanalreadycomplexequation
(cf. vitamin E).
Factors known to reactivate herpes simplex include heat
[281], 17-beta oestradiol [282] and the inﬂammatory cyto-
kine interleukin 6 [283] where a role for corticosterone has
been proposed [284]. NGF deprivation [285] also reactivates
the virus and NGF promotes viral latency via the TrkA
receptor [286] (cf. neurotrophin signalling). Vitamin A sup-
plementation in rats increases the cerebral levels of both
NGF and BDNF [129] while oestrogen deﬁciency lowers
cerebral NGF levels, an eﬀect reversed by 17-beta oestradiol
[287]. Transient cerebral ischaemia lowers NGF levels [288].
Hypoxia is also able to increase the replication of herpes
simplex [289].
Fevers induced by diverse infections might thus be ex-
pectedtoreactivateherpessimplex,aswellascerebralhypop-
erfusion. IL6 plasma and CSF levels have been reported to
be increased in Alzheimer’s disease and the secretion of IL6
frommonocytesisincreased[290–292].IL6plasmalevelsare
raised by infection with C. Pneumoniae [293]o rHelicobacter
pylori [294], and IL6 production in monocytes is stimulated
by C. Neoformans [295]. Cortisol levels are also increased in
the ageing population and in Alzheimer’s disease [296, 297].
High levels of total oestradiol have been reported as a risk
factor for Alzheimer’s disease in both women and men
[223, 224].16 ISRN Neurology
As so many other risk factors seem able to reactivate the
virus, this may be a key precipitant for the ﬁnal curtain.
Herpes simplex viral DNA is present in Alzheimer’s disease
plaques [298], and the plaques and tangles in Alzheimer’s
disease contain a very high proportion of herpes simplex
interacting proteins, as well as immune-related components.
The presence of the complement membrane attack complex
in neurones suggests that the neuronal destruction in
Alzheimer’sdiseasemightwellberelatedtotheconsequences
of battle between the virus and the immune network that has
eliminated the virus at a terrible cost of collateral neuronal
damage [33]. IgM+ antibodies, which preferentially index
HSV-1reactivation,havebeenshowntobeabletopredictthe
future risk of developing Alzheimer’s disease [208], and the
ability of other risk factors, particularly other infections, to
reactivate the virus suggests a complex interplay of genes and
risk factors that funnel towards viral reactivation and plaque
and tangle formation.
3.7. The Importance of Vitamin A. Low vitamin A levels are a
problem in the ageing population, and even in successfully
ageing persons can be observed in 50% of the population
over the age of 80–85 [299] (cf. the fox). Low vitamin A
levels are also a risk factor for Alzheimer’s disease [225].
Vitamin A plays an important role in maintaining the
immunesystem[300],manygenesofwhichareimplicatedin
Alzheimer’s disease. APP is involved in the vitamin A arena,
as a gamma57 gamma secretase cleavage product suppresses
retinoid signalling [75].
The vitamin A derivative, retinoic acid, inhibits herpes
simplex replication [301, 302]a sw e l la sc h l a m y d i a li n f e c t i o n
and growth [303]. Vitamin A also stunts the growth of
Helicobacter pylori [304]. The eﬀects of vitamin A on C.
Neoformans do not appear to have been examined. However,
glucuronoxylomannan, the polysaccharide component of
the capsular material of cryptococcus neoformans, exhibits
potent immunosuppressive properties. This compound
downregulates TNF-alpha and IL-1beta, and upregulates
the inhibitory cytokine IL-10, but also inhibits retinoic
receptor(RORG)synthesis [305].Retinoic acid isalso ableto
lower plasma homocysteine levels via the induction of hep-
atic glycine N-methyltransferase. Homocysteine in contrast
inhibits retinoic acid synthesis [306, 307].
Vitamin A levels are in fact higher in hypercholes-
terolemia patients [308]. This may perhaps be due to the
fact that retinyl palmitate, the vitamin A precursor, like
cholesterol, is also transported by lipoproteins in the blood,
mainly in the VLDL fraction (which primarily consist of
APOC2/APOE) and the LDL fraction (which primarily
consists of APOB) [41]. Retinyl palmitate concentrations in
the blood are aﬀected by APOE polymorphisms and radiola-
belled retinyl palmitate binding in total plasma and nonchy-
lomicron fractions is least in APOE4+/+ carriers [255]. The
aortic concentrations of triglycerides, total cholesterol, free
and esteriﬁed cholesterol, and phospholipids are increased
in vitamin A deﬁcient rats, an eﬀect reversed by vitamin A
supplementation [144]
A large number of Alzheimer’s disease genes are related
tovitaminA(Table2),andanev enlargern umberr esponsi v e
to retinoic acid via the action of RAR or RXR transcriptional
control.
3.8. Autoantibodies to the Antimicrobial Peptide Beta Amyloid:
LikelyDerivationfromAntibodiestoPathogens. Beta-amyloid
isapotentantimicrobialpeptide.Althoughnottestedagainst
C. Neoformans, H. pylori,o rC. Pneumoniae,i tw a sf o u n dt o
have broad spectrum activity against a variety of yeasts and
bacteria, eﬀects that were attenuated by anti-Aβ antibodies.
[309]. Lactotransferrin is also an antimicrobial peptide that
colocalises to plaques and tangle in the Alzheimer’s disease
brain [310] and other antimicrobial peptides include the
susceptibility gene products cystatin C, defensin DEFB122,
myeloperoxidase, and transferrin [88]. beta-amyloid, like
acyclovir, also attenuates the stimulatory eﬀects of HSV-
1 on miRNA-146a levels in neuronal cells [311]. The
antimicrobial and antiviral properties of beta amyloid are,
however, likely to be abrogated by the presence of beta-
amyloidantibodiesintheseraoftheageingpopulation[312]
and in Alzheimer’s disease [313].
As shown in Table 3, a number of pathogens impli-
cated in Alzheimer’s disease or its attendant risk factors,
express proteins with a high degree of homology to beta-
amyloid. These include proteins from HSV-1, HHV-6, the
cytomegalovirus, C. Neoformans, H. pylori, C. Pneumoniae,
B. Burgdorferi and, P. Gingivalis. Antibodies to B. Burgdorferi
[314]a n dC. Pneumoniae [210] and Herpes simplex and
HHV-6 viral DNA [298, 315]h a v ea l lb e e nr e p o r t e di no r
around Alzheimer’s disease plaques, and antibodies to H.
pylori recovered from Alzheimer’s disease serum and cere-
brospinalﬂuid[316].ArecentstudyshowedthatP.Gingivalis
antibodies,cross-reactivewithhumanHSP60,wereobserved
in 100% of a sample of 20 atherosclerosis patients [317]. The
immune system is not designed to raise antibodies to a self-
protein, and this high degree of homology suggests that the
autoantibodies to beta-amyloid are created by antibodies to
homologous pathogens’ proteins.
Several other autoantibodies have been reported in
Alzheimer’s disease, including targets such as nerve growth
factor [318], cholinergic neurones [319], the choroid plexus
[320], and neuroﬁbrillary tangles, inter alia [321]. The very
extensive sharing of viral and bacterial protein sequences
with the human proteome [230, 322–324] suggests that these
too might be derived from cross-reactive microbial antigens.
Again the ability to create autoantibodies is conditioned by
genes, particularly HLA-antigens [325, 326]. Autoantibodies
are often regarded as an epiphenomenon, but their ability
to traverse the blood-brain barrier [327], and the recent
recognition of their ability to enter cells [328] casts them in
a new light as pathological immunopharmacological agents
able to block the function of their target proteins: this has
indeed been shown for Alzheimer’s disease-derived ATP
synthase autoantibodies which block ATP synthesis and
cause apoptosis in neuroblastoma cells [329].
4. Summary
The classical population genetics example of the foxes and
rabbitsillustrateshowgenesandriskfactorscandiﬀerentiallyISRN Neurology 17
Table 3: Viral, bacterial, and fungal protein homology with beta-amyloid; beta-amyloid segments were compared with Borrelia Burgdorferi,
C. Neoformans, C. Pneumoniae, H. Pylori, P. Gingivalis, and herpes viruses (HSV1, HHV6, and cytomegalovirus) proteomes by BLAST
analysis. The B cell and T cell antigenicity indices are shown, and those above the server set threshold of 0.35 (B cell epitope) or 0.5 (T cell
epitope) are highlighted in bold . The ﬁrst column shows the amino acid sequence of beta-amyloid1−42 and the alignments with pathogen
proteinsareshown.Spaces represent nonidentical aminoacids and+signsamino acidswithsimilarphysicochemical properties.Onlyhighly
antigenic regions of pentapeptides or more were processed. The VGGVV sequence, antibodies to which label beta-amyloid in brain tissue,
despite relatively low antigenicity, has already been reported to be identical to proteins expressed by 69 viruses including HSV-1, HSV-2, and
HHV6 [230].
Bc e l l Tc e l l Alignments
D 0.41 0.04
+AE HDSG+ C. Neoformans DAE F H+SG EV Borrelia burgdorferi DAEF H. Pylori DA
FRH H. Pylori +AE RH HSV-1 D FR DS HHV-6 +AEFR P. Gingivalis DA EFRHD and
+AEFR +SG C. Pneumoniae
A 0.35 0.78
AEFR D GY+V C. Neoformans AEF D S YE H. pylori AE+RH+ H. pylori AEF H+ Borrelia
burgdorferi AEFR HD Cytomegalovirus AE R SG HSV-1 AE+ HD HHV-6 A+F H+S and
AEFR P. Gingivalis AEF DSG C. Pneumoniae
E 0.62 0.02 EFRHD H. Pylori EF DSG HHV-6 EFR DS Borrelia Burgdorferi EF R DS YE C. Neoformans
E R DSGY V P. Gingivalis EF SGYEV C. Pneumoniae
F 0.73 0.93 FRHDS C. Neoformans +RH SGY++ Borrelia burgdorferi F HD EV H. Pylori F H+SG H.
Pylori FR SGY Cytomegalovirus +RHDS P. Gingivalis F H+SGY C. Pneumonia
R 0.85 0.05
R D GYEV C. Neoformans R SGYE H. pylori RHDS Y V H. pylori RH+ GY Borrelia
burgdorferi RHDSG Cytomegalovirus RHD YE cytomegalovirus RH SG HSV-1 RHDS
HHV-6 R+DS Y+ P. Gingivalis
H 0.57 0.14 HDSGY C. Neoformans HD G EV H. pylori +DSGY H. pylori H+SG Y+V Borrelia
burgdorferi H+SG HSV-1 HDSG P. Gingivalis ++SGY+V C. Pneumoniae
D 0.69 0.03 DSGY+V C. Neoformans +SG+EV H. pylori DSGY HSV-1 DSG+EV P. Gingivalis DSGY V
C. Pneumoniae
S 0.38 0.02 SGYEV P. Gingivalis SGYE H. pylori SGY++ C. Neoformans SG+EV C. Pneumoniae
G 0.63 0.04 GYEVH H. pylori GYE V KL+ Borrelia Burgdorferi GYE LV and GY++ + LV C.
Neoformans GYEV P. Gingivalis GYEV and GY HH C. Pneumoniae
Y 0.56 0.96
YE HH and YE+ HQ and Y++H Q and YE HHQ H. pylori YEVH Cytomegalovirus YE+ KL
Borrelia Burgdorferi YE + QK FC. Neoformans Y++H H+K P. Gingivalis Y+V +Q LV C.
Pneumoniae
E 0.58 0.02 E V+ Q KH .p y l o r iE VH QLC y t o m e g a l o v i r u sE V+ K LB o r r e l i aB u r g d o r f e r iE VQL VC .
Neoformans EV KLV P. Gingivalis EV QKLV C. Pneumoniae
V0 . 3 5 0.90 .+H QK H. pylori V HQ LV Cytomegalovirus VH QK+V HHV-6 VH KL Borrelia
Burgdorferi +HH LV C. Neoformans VH + LV P. Gingivalis V HQKL C. Pneumoniae
H −0.17 0.10 HHQK H. pylori and C. Pneumoniae HH KL Cytomegalovirus HH KL P. Gingivalis
H −0.66 0.11 HQKL+ Borreli Burgdorferi HQKL C. Pneumoniae and HSV-1 +QKLV P. Gingivalis
Q −1.03 0.03 QKLV C. Neoformans and P. Gingivalisand C. Pneumoniae
K −1.47 0.93 KLVFF H. pylori: Cryptococcus neoformans Borrelia Burgdorferi Chlamydophila
pneumoniae KLVF Human herpesvirus 1
L −1.34 0.95 LVFF Human herpesvirus 5: Human herpesvirus 6
V −1.20 0.68
F −0.93 0.69
F −0.98 0.74
A −0.82 0.05
E −0.31 0.05
D 0.23 0.11
V 0.81 0.88 VGSNK Borrelia burgdorferi Cryptococcus neoformans Porphyromonas gingivalis +GSNK
Cytomegalovirus VGSN Helicobacter pylori Chlamydophila pneumoniae
G1 . 2 4 0.03 GSNK Helicobacter Pylori Chlamydophila pneumoniae
S1 . 2 20.03
N0 . 9 0 0.03
K0 . 3 6 0.30
G 0.30 0.1018 ISRN Neurology
Table 3: Continued.
Bc e l l Tc e l l Alignments
A −0.24 0.05
I −0.58 0.07
I −1.00 0.13
G −1.14 0.03
L −1.19 0.72
M −1.23 0.13
V −1.16 0.23 VGGVV 69 viruses/phages
G −0.97 0.03
G −1.02 0.03
V −0.63 0.23
V −0.45 0.33
I −0.80 0.95
A −1.06 0.83
permit or disallow the eﬀects of a causative agent, depending
on a permutation of circumstance. Applying this model to
Alzheimer’s disease also suggests that many of the environ-
mentalriskfactorsinAlzheimer’sdiseaseareinfactcausative
agents, at least in terms of an ability to produce beta-amyloid
deposition,perse,asshowninnontransgenicanimalmodels.
Their eﬀects are also clearly related to other risk factors
and genes. This would infer that the susceptibility genes
in Alzheimer’s disease permit the actions of these agents
but, perhaps more importantly, that polymorphisms in the
control population do not. Functional characterisation of
these control variants may provide important clues to overall
methods of protection.
Many of these risk factors are avoidable or amenable
to therapy. Diet is already known to be an important risk/
protective factor with regard to the incidence of Alzheimer’s
disease. For example there is clear evidence that the omega-
3 fatty acid docosahexaenoic acid (DHA), a component
of ﬁsh and the Mediterranean diet, also protective factors
[243, 330], is associated with a reduced risk of dementia
[331],althougharecentstudywithDHAinmildtomoderate
Alzheimer’s disease, failed to show disease arrest or diminu-
tion [332]. However, in agreement with epidemiology, DHA
signiﬁcantly beneﬁted two measures of cognition in mild to
moderatenon-ApoE4carriers[333].HighvitaminAandlow
homocysteine levels are related to a high intake of fruit and
vegetables in elderly patients [246]. Fruit and vegetable juice
consumption is also associated with reduced Alzheimer’s
disease incidence [334].
Given the fact that the potential causes of Alzheimer’s
disease appear to be multifactorial, perhaps a multifactorial
therapeutic eﬀort is also needed. Such approaches might
include a greater attention to diet, homocysteine and choles-
terol levels, vitamin A supplementation where necessary, and
the regular detection and elimination of herpes simplex,
B. Burgdorferi, C. Pneumoniae, H. pylori, C. Neoformans,
and other pathogens in the ageing population. The re-
moval of beta-amyloid antibodies and of others prevalent
in Alzheimer’s disease might also be of beneﬁt. These are
simple preventive measures, requiring public health atten-
tion, whose corporate instigation might markedly reduce the
incidence, and perhaps halt or reverse the progression, of
Alzheimer’s disease.
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